COMMUNIQUÉS West-GlobeNewswire

Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy
07/05/2026
- Initiation of Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind trial as part of Solid’s integrated, multi-trial development program designed to support registration and global regulatory [...]
Biotech’s Next Wave May Already be in Motion
07/05/2026
Insider Bets on what may become a Brain Cancer Moonshot DENVER, May 07, 2026 (GLOBE NEWSWIRE) -- ( www.247marketnews.com and NeOnc Technology) - The biotech and pharma sector is entering one of its most pivotal periods [...]
Most Vision Loss Is Preventable—20+ Eye Care, Neurology and Integrative Medicine Experts Unite for Free Global Summit This May
07/05/2026
Five-day virtual event during Healthy Vision Month in May will deliver science-based strategies for preventing vision loss and optimizing eye and brain health for patients and healthcare professionals With vision loss [...]
Virbac : Declaration of the number of shares and voting rights 04/2026
07/05/2026
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
Scarlet Therapeutics Demonstrates In Vivo Survival of Lab-Grown Universal Red Blood Cells Equivalent to Donated Blood
07/05/2026
£3.2M Seed Round Closed to Accelerate Platform Development BRISTOL, United Kingdom, May 07, 2026 (GLOBE NEWSWIRE) -- Scarlet Therapeutics ("Scarlet") today announces a landmark preclinical result: its proprietary cell- [...]
Moongrade Releases Astrology App Designed to Deliver Personalized Birth Charts and Unlimited Compatibility Insights
07/05/2026
Moongrade offers personalized birth charts and unlimited love compatibility insights for deeper self-discovery NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Moongrade has launched a personalized astrology app designed to [...]
Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease
07/05/2026
The Boards of Directors of Angelini Pharma and Catalyst Pharmaceuticals have unanimously approved the acquisition of Catalyst Pharmaceuticals at 31.50 USD per share in cash, for a total consideration of approximately 4. [...]
Virbac : Déclaration d'actions et de droits de vote 04/2026
07/05/2026
DECLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]
Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial
07/05/2026
ZUG, Switzerland, May 07, 2026 (GLOBE NEWSWIRE) -- Special Protocol Assessment (SPA) agreement with the U.S. FDA provides regulatory alignment on the registrational path for Privosegtor in optic neuritis (ON) FDA [...]
ViaNautis Bio to present its targeted polyNaut® nanovesicles (tPNVs) for the generation of in vivo CAR-T therapies at ASGCT Annual Meeting
07/05/2026
Targeted polyNaut® nanovesicles (tPNVs) are ViaNautis’ proprietary, polymer-based delivery platform for oligonucleotides enabling cell ‑ specific targeting through nanobody conjugation CD8 nanobody conjugated tPNVs are [...]
TOMI Environmental Solutions (Nasdaq: TOMZ) Clarifies Previously Announced $120M Preferred Stock LOI to Merge with Carbonium Core, Entering U.S. Nuclear-Grade Graphite Market for Advanced Reactors Within a $13–15B Global Graphite Industry
07/05/2026
Establishes domestic platform in advanced graphite, addressing a multi-billion-dollar end market underpinned by U.S. supply-chain reshoring and next-generation nuclear deployment TOMI Environmental Solutions, Inc. and [...]
Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial
07/05/2026
Special Protocol Assessment (SPA) agreement with the U.S. FDA provides regulatory alignment on the registrational path for Privosegtor in optic neuritis (ON) FDA Breakthrough Therapy and EMA PRIME designations in ON [...]
Zealand Pharma - Execution framework for share buy-back program
07/05/2026
Company announcement No. 15 / 2026 Zealand Pharma - Execution framework for share buy-back program Copenhagen, Denmark, May 7, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. [...]
Zealand Pharma Announces Financial Results for the First Three Months of 2026
07/05/2026
Company announcement – No. 14 / 2026 Zealand Pharma Announces Financial Results for the First Three Months of 2026 A defining start to 2026, marked by pivotal progress for leading obesity assets, petrelintide and [...]
Zelluna ASA: First Quarter 2026 results
07/05/2026
Oslo, 7 May 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today presents its results for the [...]
Pharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disorders
07/05/2026
Leiden, the Netherlands, May 7, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced presentations at the 2026 Annual Meeting of the Clinical Immunology [...]
Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026
07/05/2026
First quarter 2026 total revenues were US$72.4 million, an 8% decrease compared to the first quarter 2025 RUCONEST® revenue was US$58.4 million, a 15% decrease compared to the first quarter 2025, mainly due to [...]
Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics
07/05/2026
PathAI’s best-in-class Image Management System (IMS) with advanced AI analysis and workflow capabilities will complement Roche's digital pathology portfolio to drive laboratory efficiency Combining Roche’s strong [...]
Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease
07/05/2026
The Boards of Directors of Angelini Pharma and Catalyst Pharmaceuticals have unanimously approved the acquisition of Catalyst Pharmaceuticals at 31.50 USD per share in cash, for a total consideration of approximately 4. [...]

Pages